Information

The study aims to see the use of Rifapentine, Isoniazid, Pyrazinamide, and Moxifloxacin Combination for 4 months for Drug-Sensitive Tuberculosis Patients in Indonesia

Kementerian Kesehatan Republik Indonesia

Type of Study

Stakeholders Involved

Operational Study

Background

One of the challenges in TB treatment is patient compliance due to the long duration of treatment. Shorter duration regimens can reduce TB incidence and mortality by 27% and 25% by 2050. In 2022, WHO recommends a four-month 2HPMZ/2HPM scheme. Therefore, operational research was conducted to evaluate the effectiveness, acceptability, and safety of the HPMZ strategy.

Gallery